Vanda Pharmaceuticals (VNDA) Tops Q2 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
- Wall Street posts weekly gains with earnings, inflation data on tap
- Oil prices settle higher as more production shut ahead of hurricane
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
- US consumer sentiment near record low as frustration over economy mounts
- 8.0 Mag. Earthquake 14 Km Sw Of Pitaloza Arriba Panama - USGS
- Strong Panama quake damages buildings, disrupts power and air travel
- SpaceX to acquire Grain Management's 800 MHz spectrum portfolio
- CoreWeave stock drops on dilution fears and debt concerns
Vanda Pharmaceuticals Reports Second Quarter 2020 Financial Results
August 5, 2020 4:01 PM EDTWASHINGTON, Aug. 5, 2020 /PRNewswire/ --Â Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the second quarter ended June 30, 2020.
"We are very proud of the achievements of our team, especially the record commercial performance, even in the face of the challenges presented by the pandemic. We are also very excited with the progress of the HETLIOZ® SMS applications as we get closer to providing a therapeutic solution to patients with SMS," said Mihael H. Polymeropoulos, M.D., Vanda's President and CEO.
Key Financial and Corporate... More



